信迪利单抗联合仑伐替尼治疗晚期原发性肝癌的疗效和安全性分析

肝脏 ›› 2024, Vol. 29 ›› Issue (12): 1480-1483.

信迪利单抗联合仑伐替尼治疗晚期原发性肝癌的疗效和安全性分析

田昳程, 唐祖雄, 汝干, 王奇, 翟春涛

215000 江苏苏州科技城医院(田昳程,汝干,王奇,翟春涛);苏州大学附属第一医院(唐祖雄)

收稿日期:2024-06-22 出版日期:2024-12-31 发布日期:2025-02-19
通讯作者: 翟春涛

An analysis on the efficacy and safety of sintilimab combined with lenvatinib in the treatment of advanced hepatocellular carcinoma

TIAN Yi-cheng¹, TANG Zu-xiong², RU Gan¹, WANG Qi¹, ZHAI Chun-tao¹

1. Suzhou Science&Technology Town Hospital, Jiangsu 215000, China;
2.The First Affiliated Hospital of Soochow University,Jiangsu 215000,China

Received:2024-06-22 Online:2024-12-31 Published:2025-02-19
Contact: ZHAI Chun-tao

摘要/Abstract

摘要： 目的分析信迪利单抗联合仑伐替尼治疗晚期原发性肝癌(HCC)的疗效及安全性。方法收集2021年1月至2023年12月苏州科技城医院和苏州大学附属第一医院收治的68例晚期HCC患者的临床资料。对照组34例患者接受仑伐替尼单药治疗,观察组34例患者接受信迪利单抗联合仑伐替尼治疗。评估患者生命体征和实验室结果直到死亡、失去联系或研究结束,采用实体肿瘤疗效评价标准(mRECIST)评估抗肿瘤反应,绘制生存曲线,记录治疗期间不良事件发生情况。结果两组患者基线临床资料和治疗期间不良事件发生情况比较,差异均无统计学意义(P>0.05)。观察组中位无进展生存期(PFS)为11.5个月,对照组为6.8个月,差异有统计学意义(P=0.013,HR=0.568,95% CI:0.359~0.886)。观察组中位总生存期(OS)为21.5个月,对照组为12.7个月,差异有统计学意义(P=0.005,HR=0.426,95% CI:0.237~0.782)。治疗后观察组患者客观缓解率(ORR)和疾病控制率(DCR)分别为44.12%和85.29%,对照组患者分别为23.53%和58.82%,差异有统计学意义(P<0.05)。结论信迪利单抗联合仑伐替尼治疗晚期HCC安全有效,比仑伐替尼单药治疗具有更好的长期预后。

关键词: 原发性肝癌, 信迪利单抗, 仑伐替尼, 疗效, 安全性

Abstract: Objective To analyze the efficacy and security of sintilimab combined with lenvatinib in the treatment of advanced hepatocellular carcinoma (HCC).Methods A total of 68 patients with advanced HCC were selected from January 2021 to December 2023 as the research subjects. Thirty-four patients in the control group received lenvatinib monotherapy, and 34 patients in the observation group received sintilimab combined with lenvatinib treatment. Patients' vital signs and clinical laboratory results were continuously evaluated until they died, lost contact, or the study was ended. The antitumour response was assessed using the HCC specific modified RECIST (mRECIST), the survival curves were plotted and the occurrence of adverse events during treatment was recorded.Results There were no significant differences in the baseline clinical data and the occurrence of adverse events during treatment between the two groups (P＞0.05). The median PFS were 11.5 months and 6.8 months in two groups, with significant difference (P=0.013, HR=0.568, 95%CI=0.359-0.886). The median OS were 21.5 months and 12.7 months in two groups, with significant difference (P=0.005, HR=0.426, 95%CI=0.237-0.782). After treatment, the ORR and DCR were 44.12% and 85.29%, respectively, in the observation group, and were 23.53% and 58.82% in the control group, with significant differences (P＜0.05).Conclusion Sintilimab combined with lenvatinib is effective and safe in the treatment of advanced HCC and may lead to a better long-term outcome than lenvatinib monotherapy.

Key words: Hepatocellular carcinoma, Sintilimab, Lenvatinib, Efficacy, Security

田昳程, 唐祖雄, 汝干, 王奇, 翟春涛. 信迪利单抗联合仑伐替尼治疗晚期原发性肝癌的疗效和安全性分析[J]. 肝脏, 2024, 29(12): 1480-1483.

TIAN Yi-cheng, TANG Zu-xiong, RU Gan, WANG Qi, ZHAI Chun-tao. An analysis on the efficacy and safety of sintilimab combined with lenvatinib in the treatment of advanced hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(12): 1480-1483.

/ 推荐

参考文献

[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2019, 394(10204): 1145-1158.
[2] Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma [J]. J Exp Clin Cancer Res, 2019, 38(1): 447.
[3] Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy [J]. Curr Oncol, 2022, 29(5): 3044-3060.
[4] Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights [J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
[5] Yi C, Chen L, Lin Z, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC [J]. Hepatology, 2021, 74(5): 2544-2560.
[6] Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements [J]. J Hepatol, 2020, 72(2): 288-306.
[7] Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies [J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.
[8] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[9] Tümen D, Heumann P, Gülow K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma [J]. Biomedicines, 2022, 10(12): 3202.
[10] Vogel A, Qin S, Kudo M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2021, 6(8): 649-658.
[11] Li Q, Han J, Yang Y, et al. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy [J]. Front Immunol, 2022, 13: 1070961.
[12] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma [J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[13] Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway [J]. PLoS One, 2019, 14(2): e0212513.

[1]	朱继兰, 赵霞, 王市伟, 杨蕾. 多参数磁共振成像联合CT动态增强对晚期肝细胞癌免疫治疗疗效的预测价值[J]. 肝脏, 2024, 29(9): 1040-1046.
[2]	徐颖, 季汉超, 张海军, 徐静. KRAS基因突变对中晚期原发性肝癌患者经DEB-TACE治疗后生存期的预测价值[J]. 肝脏, 2024, 29(9): 1047-1051.
[3]	董燕兵, 牛猛, 罗月宾, 闻听亮. 信迪利联合靶向治疗中晚期原发性肝癌的临床研究[J]. 肝脏, 2024, 29(9): 1068-1073.
[4]	钱叶强, 高路, 余春来. 酪氨酸激酶抑制剂联合肝动脉化疗栓塞治疗肝细胞癌的近远期疗效[J]. 肝脏, 2024, 29(7): 780-783.
[5]	陈延霞, 阿妮, 徐旋, 白荣, 刘小治. 增强MRI多模态参数与原发性肝癌患者肝功能分级的相关性分析[J]. 肝脏, 2024, 29(6): 667-670.
[6]	蒋仕伍, 彭晓燕, 陈均源, 封斐耀, 刘美玲. TACE联合替雷利珠单抗治疗中晚期原发性肝癌的临床价值[J]. 肝脏, 2024, 29(6): 676-680.
[7]	马志刚, 刘丽丽, 王旭, 冯鹏丽, 杨帆, 杨永宾. 经颈静脉肝内门体静脉分流术对肝硬化门静脉高压症患者门静脉直径及远期疗效的影响[J]. 肝脏, 2024, 29(5): 516-520.
[8]	郝苑苑, 王君, 徐大超. 超声造影评估微波消融治疗特殊部位原发性肝癌患者的价值[J]. 肝脏, 2024, 29(5): 526-529.
[9]	杨菁菁, 李莎, 蔡明月. 增强CT纹理参数在HBV相关肝细胞癌介入治疗效果评估中的应用[J]. 肝脏, 2024, 29(5): 534-537.
[10]	杨利平, 于杰, 李勤英, 夏艳, 齐高昂, 尚芮, 武龙君, 高磊. 超声引导下微波消融对复发性肝癌长期疗效的影响因素研究[J]. 肝脏, 2024, 29(2): 189-192.
[11]	张永红, 储建华, 陈国栋. Callispheres-TACE术联合信迪利单抗治疗不可切除肝细胞癌的有效性[J]. 肝脏, 2024, 29(2): 202-207.
[12]	张贝克, 范永刚, 张莹楠, 姚国良. 血清肿瘤异常蛋白、平均血小板体积/淋巴细胞比值与腹腔镜肝癌切除术患者预后的关系[J]. 肝脏, 2024, 29(12): 1489-1492.
[13]	舒佳桔, 叶细容. 超声引导下微波消融联合卡瑞利珠单抗治疗中晚期原发性肝癌的疗效观察[J]. 肝脏, 2024, 29(12): 1493-1497.
[14]	菅辉玲, 高丽霞, 李桂圆, 朱海鹏, 李砥, 贾晓玲, 胡军. 联合检测血清APE1、miR183在原发性肝癌诊断中的价值[J]. 肝脏, 2024, 29(12): 1498-1502.
[15]	张自强, 陈凯荣, 吴俊, 刘金龙, 马峰. 原发性肝癌患者血清miR-15b-5p、miR-145与TACE治疗预后不良的关系[J]. 肝脏, 2024, 29(12): 1503-1507.